Rosales-Calderón M, Pérez-Enríquez B

Language: Spanish
References: 18
Page: 51-54
PDF size: 158.11 Kb.

ABSTRACT

NO ABSTRACT

REFERENCES

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.

2. Shaha A. Treatment of thyroid cancer based on risk groups. J Surg Oncol 2006; 94: 683-691.

3. Gagel RF, Goepfert H, Callender DL. Changing concepts in the pathogenesis and management of thyroid carcinoma. CA Cancer J Clin 1996; 46: 261-283.

4. Enewold L, Zhu K, Ron E et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1988-2005. Cancer Epidemiol Biomarkers Prev 2009; 18: 784-791.

5. Chen AY, Jamal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer 2009; 115: 3801-3807.

6. Cooper DS, Doherty GM, Haugen BR et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1159-1165.

7. Pacini F, Schlumberger M, Dralle H et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006; 154: 787-803.

8. Elisei R, Schlumberger M, Driedger A et al. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. J Clin Endocrinol Metab 2009; 94: 4171-4179.

9. Pacini F, Ladenson PW, Schlumberger M et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 2006; 91: 926-932.

10. Implementing QALYs. Hayward Medical Communications. March 2001. Disponible en: www.medicine.ox.ac.uk/bandolier/painres/download/whatis/ImplementQALYs.pdf

11. Kopec JA, Willison KD. A comparative review of four preference-weighted measures of health-related quality of life. J Clin Epidemiol 2003; 56: 317-325.

12. Ware JE, Gandek B. Overview of the SF-36 health survey and the international quality of life assessment (IQOLA) project. J Clin Epidemiol 1998; 51: 903-912.

13. Mernagh P, Campbell S, Dietlein M, Luster M, Mazzaferri E, Weston A. Cost-effectiveness of using recombinant human TSH prior radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: the German perspective. Eur J Endocrinol 2006; 155: 405-414.

14. Mernagh P, Suebwongpat A, Silverberg J, Weston AA. Cost-effectiveness of using recombinant human TSH before radioiodine ablation for thyroid cancer: the Canadian Perspective. Value Health Publicado en línea 8 Oct 2009. [Epub ahead of print]. DOI: 1098-3015/09/.

15. Blamey S, Barraclough B, Delbridge L, Mernagh P, Standfield L, Weston A. Using recombinant human thyroid-stimulating hormone for diagnosis of recurrent thyroid cancer. ANZ J Sur 2005; 75: 10-20.

16. Giovanella L, Ceriani L, Ghelfo A et al. Thyroglobulin assay during thyroxine treatment in low-risk differentiated thyroid cancer management: Comparison with recombinant human thyrotropin-stimulated assay and Imaging procedures. Clin Chem Lab Med 2006; 44: 648-652.

17. Rosario PW, Purisch S. Does a highly sensitive thyroglobulin (Tg) assay change the clinical Management of low risk patients with thyroid cancer with Tg on T4 < 1 ng/mL determined by traditional assays? Clin Endocrinol 2008; 68: 338-342.

18. Iervasi A, Iervasi G, Ferdeghinit M et al. Clinical relevance of highly sensitive Tg assay in monitoring patients treated for differentiated thyroid cancer. Clin Endocrinol 2007; 67: 434-441.